Valneva SE revenue

Valneva SE's revenue was $197m in fiscal 2025, up 7.6% on the year before. Since fiscal 2019 ($141m) it has grown at a compound 5.7% a year.

Revenue history

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Valneva SE: revenue history, annual
Fiscal year	2019Dec 2019	2020Dec 2020	2021Dec 2021	2022Dec 2022	2023Dec 2023	2024Dec 2024	2025Dec 2025
Revenue	141	126	412	381	166	183	197
Growth on the year before	—	−10.9%	+227.1%	−7.6%	−56.3%	+10.4%	+7.6%
Gross profit	82	64	189	39	57	77	76
Gross margin	58.2%	50.8%	46.0%	10.2%	34.4%	41.9%	38.7%

Revenue as reported in the company's 10-K and 10-Q filings (for banks, net interest income plus non-interest income). Growth is left blank when the earlier figure was zero or negative.

Revenue against peers

Biotechnology: the closest covered companies by revenue. Last twelve months.

Company	Revenue	Growth	3-year growth a year
Valneva SE	$197m	7.6%	—
Urogen Pharma Ltd.	$189m	100.3%	37.6%
Arbutus Biopharma Corp	$182m	1078.8%	97.6%
Akebia Therapeutics, Inc.	$219m	7.5%	2.9%
Nuvation Bio Inc.	$170m	1083.6%	—
Puma Biotechnology, Inc.	$231m	-2.9%	0.2%

Compare with peers

Head to head: URGN vs VALN ABUS vs VALN AKBA vs VALN

More: Biotechnology stocks compared, Health Care sector, rankings of US companies

Figures from Valneva SE's SEC filings (10-K and 10-Q), retrieved November 1, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Valneva SE.